Company Description
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA.
Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA.
Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019.
The company was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Zachary Hornby |
Contact Details
Address: 9880 Campus Point Drive, Suite 120 San Diego, California 92121 United States | |
| Phone | 858 766 9912 |
| Website | boundlessbio.com |
Stock Details
| Ticker Symbol | BOLD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782303 |
| ISIN Number | US10170A1007 |
| Employer ID | 83-0751369 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zachary Hornby | Chief Executive Officer, President and Director |
| Dr. Jonathan E. Lim M.D. | Co-Founder and Independent Chairman |
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer |
| Dr. Klaus W. Wagner M.D., Ph.D. | Chief Medical Officer |
| David Hinkle | Senior Vice President of Finance and Controller |
| Jessica Oien J.D. | Chief Legal Officer and Corporate Secretary |
| Neil Abdollahian M.B.A., M.S. | Chief Business Officer |
| Anthony Pinkerton Ph.D. | Senior Vice President of Drug Discovery |
| Meredith Wesley | Senior Vice President of Talent and Culture |
| Dr. Shailaja Kasibhatla Ph.D. | Senior Vice President of Discovery and Translational Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 29, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 15, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 8-K | Current Report |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| Apr 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |